 Braxia Scientific Corp has posted strong revenue in its fiscal first quarter to June 30, 2021, as it saw more patients and administered more ketamine infusion treatments at its four Canadian clinics. The company, which is focused on treatments for depression and related conditions, said revenue in the three-month period came in at C407,075, with gross margin of 114,253, representing increases of 80.3 and 89.7 respectively compared to the first fiscal quarter of 2020. 